바이킹 테라퓨틱스(VKTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $33.19 (+0.76%), 시가총액 $3.68B, 52주 범위 $23.09 ~ $42.09.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metab
바이킹 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
바이킹 테라퓨틱스의 현재 주가는 $33.19 (+0.76%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
바이킹 테라퓨틱스의 시가총액은 약 $3.68B입니다.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally